Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Spyre Therapeutics (NASDAQ: SYRE) Meets SKYWAY-RA Endpoints but Redirects Focus; Shares Close Down 13%

The distinction sits at the centre of this result. Statistical significance answers whether an observed difference is unlikely to be chance. Magnitude of effect answers how large that difference is. A trial can clear the first test and still produce an effect size that …

Nitish Kishor | 27 August 2026

Addex Therapeutics (NASDAQ: ADXN) Raises USD 2.8 Million Through ATM Programme, Extends Runway to Q4 2027

An at-the-market programme allows a company to sell new shares into the open market over time at prevailing prices through a designated agent, rather than raisingCapitalin a single marketed offering. It gives flexibility on timing and avoids the discount typically attached to a placement. …

Nitish Kishor | 27 August 2026

Biohaven (NYSE: BHVN) Licenses Kv7 Platform to SK Biopharmaceuticals in Deal Worth up to USD 795 Million; Shares Close Up 18%

The two figures do different work. USD 400 million is capital Biohaven receives now. The USD 795 million total is the ceiling if every milestone in the agreement is achieved, which places roughly USD 395 million in contingent payments beyond the immediate amount. Royalties …

Nitish Kishor | 27 August 2026

AEON Biopharma (NYSE: AEON) Appoints Former FDA Official Paul Lee as Acting Chief Regulatory Officer; Shares Close Up 19%

Section 351(k) of the Public Health Service Act is the abbreviated licensure route for biosimilars. An applicant must demonstrate that its product is highly similar to an already licensed reference biologic with no clinically meaningful differences, which typically requires analytical, non-clinical and clinical comparability …

Nitish Kishor | 27 August 2026

Capricor Therapeutics (NASDAQ: CAPR) Details HOPE-3 Upper-Limb Results and USD 237.9 Million Cash Position; Shares Close Up 13%

A Biologics License Application amendment supplements a pending submission with additional information rather than starting a new one. Here the addition is 24-month open-label safety data. Longer-duration safety follow-up addresses durability of the safety profile, which is a common area of focus where a …

Nitish Kishor | 27 August 2026

Seaport Therapeutics (NASDAQ: SPTX) Initiated at Buy by Jones Trading With USD 32 Price Target; Shares Close Up 12%

The USD 32 target sits roughly 15 per cent above the USD 27.84 closing price on the day. That is the arithmetic gap between the two figures and nothing more. A price target is one firm’s estimate of where a stock may trade over …

Nitish Kishor | 27 August 2026

Nuwellis (NASDAQ: NUWE) Starts Six-Month AtriAmp Pilot With Atrility Medical

Two features define the deal as announced. The first is duration. Six months is a defined trial period rather than an open-ended commercial agreement, so the arrangement carries a review point built into it. The second is geography. Distribution rights apply to specific United …

Nitish Kishor | 27 August 2026

Celularity (NASDAQ: CELU) Receives Nasdaq Notice Over Delinquent Q1 and Q2 2026 Form 10-Q Filings

A Form 10-Q is the interim periodic report that a domestic reporting company files for the first three quarters of its fiscal year. It carries unaudited financial statements and management discussion for the quarter. With two consecutive 10-Q filings outstanding, the most recent financial …

Nitish Kishor | 27 August 2026

Summit Therapeutics (NASDAQ: SMMT) Reports Akeso Phase 3 Overall Survival Result for Ivonescimab in First-Line Biliary Tract Cancer

Overall survival was the measure on which superiority was reported. The announcement also stated that the secondary endpoints of progression free survival and objective response rate were met. Summit stated the result supports the broader clinical profile of ivonescimab ahead of a full data …

Nitish Kishor | 27 August 2026

First Resources (OTC:FSRCY) Interim Payout Rides a 57% Profit Surge on Palm-Oil Prices

First Resources'Interim Dividendyields approximately 3.85%, a figure that looks especially generous set against a first half where net profit jumped 57%. The catch is that this payout is riding aCommoditytailwind in palm-oil pricing, not a structural improvement in the business, meaning the yield could …

Nitish Kishor | 26 August 2026
Support

Hi! How can we help you today?

Loading…